XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma

NCT06571734 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Leiomyosarcoma
Unresectable Leiomyosarcoma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Echocardiography
PROCEDURE: Multigated Acquisition Scan
DRUG: Zanzalintinib

Sponsor

Northwestern University

Collaborators

[object Object]